e-learning
resources
Vienna 2003
Tuesday 30.09.2003
Pulmonary hypertension
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Patients with primary or thromboembolic pulmonary hypertension develop renal resistance to ANP and BNP
A. Charloux, A. Chaouat, F. Piquard, G. Brandenberger, S. Doutreleau, E. Weitzenblum (Strasbourg, France)
Source:
Annual Congress 2003 - Pulmonary hypertension
Session:
Pulmonary hypertension
Session type:
Thematic Poster Session
Number:
2934
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Charloux, A. Chaouat, F. Piquard, G. Brandenberger, S. Doutreleau, E. Weitzenblum (Strasbourg, France). Patients with primary or thromboembolic pulmonary hypertension develop renal resistance to ANP and BNP. Eur Respir J 2003; 22: Suppl. 45, 2934
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The definition of pulmonary hypertension: history, practical implications and current controversies
Should we screen for hereditary pulmonary hypertension?
Patient with ankylosing spondylitis and pulmonary hypertension
Related content which might interest you:
Plasma big-endothelin and hemodynamics in patients with pulmonary arterial hypertension compared to patients with chronic left heart failure with and without pulmonary venous hypertension
Source: Annual Congress 2009 - Pulmonary circulation I
Year: 2009
Brain natriuretic peptides in patients with idiopathic pulmonary hypertension and chronic thromboembolic disease
Source: Annual Congress 2007 - Venous thromboembolic disease
Year: 2007
Comparison of NT-proBNP and BNP in the diagnosis of pulmonary hypertension – influence of renal impairment
Source: Eur Respir J 2006; 28: Suppl. 50, 425s
Year: 2006
Sitaxentan-induced hepatic failure in two patients with pulmonary arterial hypertension
Source: Eur Respir J 2009; 34: 770
Year: 2009
N-terminal-pro-brain natriuretic peptide as a haemodynamic marker in idiopathic pulmonary arterial hypertension
Source: Eur Respir J 2005; 25: 509-513
Year: 2005
Pulmonary function in patients with idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
Source: Annual Congress 2010 - Pulmonary circulation I
Year: 2010
Surgical and post-operative treatment of chronic thromboembolic pulmonary hypertension
Source: Eur Respir Rev 2009; 19: 64-67
Year: 2010
Adherence to disease-specific drug treatment among patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension
Source: ERJ Open Res, 6 (4) 00299-2020; 10.1183/23120541.00299-2020
Year: 2020
NT-proBNP variation in stable pulmonary arterial hypertension patients.
Source: International Congress 2018 – Pulmonary hypertension in lung diseases and the role of the right ventricle
Year: 2018
Platelet function in patients with chronic thromboembolic pulmonary hypertension
Source: Annual Congress 2009 - Acute and chronic venous thromboembolic disease
Year: 2009
Comparison of clinical characteristics in patients with pulmonary arterial hypertension and inoperable chronic thromboembolic pulmonary hypertension
Source: Annual Congress 2008 - Pulmonary venous thromboembolic disease
Year: 2008
Prognostic factors of acute heart failure in patients with pulmonary arterial hypertension
Source: Eur Respir J 2010; 35: 1286-1293
Year: 2010
Evaluation of serum cytokines in patients with idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension with hypercholesterolemia
Source: International Congress 2017 – PAH and CTEPH
Year: 2017
Hemodynamic correlates of endothelin-1 in chronic thromboembolic pulmonary hypertension
Source: Eur Respir J 2004; 24: Suppl. 48, 110s
Year: 2004
The impact of immediate postoperative pulmonary vascular resistance on survival in patients with chronic thromboembolic pulmonary hypertension
Source: Annual Congress 2009 - Pulmonary embolism
Year: 2009
Continuous intravenous epoprostenol for chronic thromboembolic pulmonary hypertension
Source: Eur Respir J 2004; 23: 595-600
Year: 2004
Acute hemodynamic effects of riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
Source: International Congress 2018 – Pulmonary hypertension: therapy
Year: 2018
Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
Source: Eur Respir J, 53 (6) 1802004; 10.1183/13993003.02004-2018
Year: 2019
Vasodilator treatment in chronic thromboembolic pulmonary hypertension
Source: Annual Congress 2003 - Update on chronic thromboembolic pulmonary hypertension
Year: 2003
ERS statement on chronic thromboembolic pulmonary hypertension
Source: ERS webinar 2021: ERS statement on chronic thromboembolic pulmonary hypertension
Year: 2021
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept